

# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, Wim Van Paesschen

Organisation/Company: N/A

Country: Belgium

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

#### 1.1 Employment

No interest declared

#### 1.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Current	01-06-2022	22-03-2023	Angelini Pharma	Individual product related	Cenobamate	epilepsy	null
Current	01-03-2022	22-03-2023	Byteflies NV	Individual product related	Sensor Dot (wearable)	epilepsy	null

#### 1.3 Strategic advisory role

No interest declared

#### 1.4 Financial interests

No interest declared

#### 1.5 Principal investigator

No interest declared

#### 1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-06-2010	01-11-2016	UCB PHARMA	Sodium OXYBATE	Narcolepsy
Current	01-08-2022	22-03-2023	Neurocrine Biosciences	NBI_921352	epilepsy
Past	01-02-2006	01-12-2011	Valeant	Retigabine	epilepsy
Past	01-07-2014	01-04-2015	Upsher_Smith Laboratories	Midazolam	epilepsy
Past	01-09-	01-12-	Elan Pharmaceuticals	Zonisamide	epilepsy

	2001	2004			
Past	01-09-2004	01-06-2006	Pfizer	Pregabalin	epilepsy
Past	01-09-2002	01-01-2006	Warner_Lambert (Pfizer)	Pregabalin	epilepsy
Past	01-08-2007	01-12-2011	Eisai	E2007 (Perampanel)	epilepsy
Past	01-07-2017	01-10-2018	Jazz_Pharmaceuticals	JZP 258	Narcolepsy
Past	01-12-2004	01-06-2016	UCB Pharma	Brivaracetam	epilepsy
Past	01-05-2015	01-04-2019	UCB Biopharma	UCB0942/Padsevonil	epilepsy
Past	01-01-2015	01-08-2016	Eisai	Perampanel	epilepsy
Past	01-06-2014	01-06-2016	NOVARTIS PHARMA	EVEROLIMUS	EPILEPSY IN TUBEROUS SCLEROSIS
Past	01-07-2010	01-12-2012	Upsher_Smith	USL255	epilepsy
Past	01-05-2005	01-12-2009	Johnson&Johnson	RWJ_333369	epilepsy
Past	01-06-2010	01-06-2018	UCB BIOSCIENCES GMBH	LACOSAMIDE	EPILEPSY
Past	01-05-2002	01-08-2008	UCB Pharma	Levetiracetam	epilepsy
Past	01-07-2004	01-12-2009	Bial_Portela	BIA 2_093	epilepsy
Past	01-08-2019	01-06-2020	UCB Pharma	Padsevonil (Duet study)	epilepsy

### 1.7 Grant / Funding to organisation /institution

No interest declared

### 1.8 Close family member interest

No interest declared

### 1.9 Repurposing of a medicinal product

No interest declared

### 1.10 Any other interests or facts

No interest declared

### 1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## 2.1 Employment

No interest declared

## 2.2 Consultancy

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Current	01-01-2016		Byteflies NV	Individual product related	Sensor Dot	epilepsy	

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Current	01-01-2018		Byteflies NV	Sensory Dot	epilepsy

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

---

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name: Wim Van Paesschen

Date: 2023-06-22

For definitions of activities etc, refer to the policy on handling of competing interests.